Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific
Released today, 'On the Cusp of a Cure' White Paper examines Asia Pacific's readiness for the Precision Era – the current, transformative period where generically prescribed and regularly administered treatments are increasingly giving way to potentially curative therapies tailored to individuals and their disease. Treatments called precision therapies.
Across the four markets over the next 10 years, the new research by L.E.K. Consulting and an advisory committee of 16 Asia Pacific experts using a proprietary 'whole system benefits modelling' approach found that the Precision Era has the potential to:
Drive direct economic investment of approximately USD 450 billion.[i]
Create almost 1.2 million highly skilled jobs[i] in R&D, advanced manufacturing and biotechnology.
Drive USD1.615 trillion in broader[i], indirect economic benefit via a multiplier effect across adjacent industries.
Save healthcare systems across the four markets USD 39 billion[i], alleviating intense pressure on resources.
Increase workforce participation for 24 million patients and caregivers by improving their ability to return or stay in work.[i]
"The Precision Era is being driven by the arrival of a critical mass of some 4,000 innovative cell and gene therapies that will redefine treatment, attract investment and improve lives. Never before have we had such a clear view of the huge potential that this new era holds for Asia-Pacific. Healthcare systems stand to save billions, and patients could potentially live healthier for longer. The broader economic impact of this new era medicine is equivalent to South Korea's annual GDP, and the potential for new jobs greater than the entire population of Adelaide," said Stephanie Newey, Managing Partner, Head of L.E.K. Consulting Australia.
Precision therapies put us on the cusp of a cure
The 'On the Cusp of a Cure' research assessed data from more than 1,000 clinical trials across four novel technologies – gene therapies, targeted antibody therapies, drug-device combination therapies, and diagnostic technologies. These precision therapies are considered part of the Precision Era because they provide enhanced health benefits through a more tailored approach, represent a paradigm shift to how care has been provided previously and are the focus of significant research and investment.
Critically, some experts suggest we may be on the cusp of a cure for diseases that have previously been considered incurable and represent Asia-Pacific's most pressing health challenges, such as many cancers and genetic disorders.
"Asia disproportionately carries the largest cancer and rare disease burden in the world. It shoulders nearly half of all global cancer incidence[ii] and is home to 258 million people who are living with rare diseases[iii]. Worse still, these numbers are only expected to grow, fuelling calls for sustainable, scalable and effective solutions. Precision therapies are stepping forward to meet this critical need and represent a new standard of care for many of Asia-Pacific's health challenges," said Professor Baorong Yu, from the University of International Business and Economics in China.
One of the most groundbreaking examples of these treatments is chimeric antigen receptor T-cell (CAR-T) therapy that modifies the body's own T cells (a type of white blood cell) to target and destroy cancer cells[iv]. It is commonly used in the treatment of blood cancers, which has a 50% survival rate for over a third of patients. Currently, these patients are mostly treated through chemotherapy and radiotherapy, but many do not respond or will relapse.
"With increased access to innovative treatments such as CAR-T therapy, particularly earlier in treatment regimes, patients could live longer with a better quality of life," said Naomi Sakurai, Advisory Committee member and Founder and CEO, Cancer Solutions. "Rather than going through multiple rounds of chemo, they would have a therapy tailored specifically to their condition. These precision treatments are now offering hope by potentially curing once-incurable diseases and giving people the priceless gift of more time with their loved ones."
What's holding back the adoption of precision therapies?
The Precision Era brings fundamental change to the way disease is approached and how patients are treated, and requires an equivalent rethink from regulators and policymakers.
While each market has its own, unique policy environment, 'On the Cusp of a Cure' series found that Australia, China, Japan, and South Korea all exhibit similar barriers to precision therapy adoption. Rules remain unclear for evaluating the reimbursement of new precision therapies, there is limited awareness among patients and doctors about these treatments, and better healthcare infrastructure is needed to support access.
The 'On the Cusp of a Cure' research presents a number of regional solutions to unlock the potential benefits of precision therapies:
Establish streamlined regulatory and reimbursement pathways specifically tailored for these treatments
Increase education for providers, patients, and the community to enhance understanding of the Precision Era
Enhance public-private collaboration to foster innovation and equitable access to precision therapies.
Improve access and affordability through pricing strategies, reimbursement frameworks, and insurance initiatives for treatments and diagnostics alike.
Through clinical guidelines and knowledge sharing, empower HCPs to make informed decisions about precision therapies, and assist patients in complex treatment paths.
By backing local industry investments in therapies and diagnostics, and nurturing expertise, joint efforts can drive sustainable progress towards transformative innovations.
"With this new era of precision therapies, we stand at the threshold of transforming healthcare across Asia-Pacific," said Sakurai. "But for the full potential of these medicines to materialise, regulatory systems as well as knowledge and infrastructure must keep up. The goal of precision therapies is to ensure the right patient, right timing, right treatment and right dose. We all have a role to play, including policymakers, healthcare professionals, and healthcare industry leaders, to remove barriers for patients to these potentially life-changing therapies."
"On the Cusp of a Cure White Paper Asia Pacific Series is made up of four local market white papers evaluating barriers to precision therapy adoption, providing recommendations for improvement, and assessing the value of widespread adoption in Australia, China, Japan, and Korea.
Notes to Editor: On the Cusp of a Cure White Paper Series and Advisory Committee Members
The On the Cusp of a Cure whitepaper series was supported by an advisory committee of 16 pre-eminent regional experts in precision medicine, economic and health policy, and patient experience across Australia, China, Japan and Korea. It was also sponsored by Johnson & Johnson.
Australia
China
South Korea
Japan
David Thomas, Chief Scientific Officer, Omico
Jaala Pulford, Chair of the Board, MTPConnect
Christine Cockburn, CEO, Rare Cancers Australia
Baorong Yu, Professor and market access key opinion leader, University of International Business and Economics
Andy Mok, Head of China, Guardant Health
Kevin Huang, Founder and president, China Organization for Rare Disorders (CORD)
Caicun Zhou, Professor and lung cancer key opinion leader, School of Medicine, Tongji University
Paul Lee, Former GM, Gilead Sciences Korea
Jin-Ah Kim, Advocate for rare diseases, Seoul National University Hospital, Department of Genomic Medicine, Rare Disease Centre
Prof Jeonghoon Ahn, Professor of Health Convergence, Ewha University
Teruyuki Katori, Representative Director, Special Appointed Professor, Future Institute Wolong, General Incorporated Association Graduate School of Social Sciences, University of Hyogo
Daisuke Sato, Professor. Fujita Health university
Manabu Muto, Professor, Kyoto University Graduate School of Medicine
Masahiro Miyake, Professor, Kyoto University Hospital
Naomi Sakurai, Founder and CEO, Cancer Solutions
Keisuke Shimizu, Leader, Lung cancer HER2 "HER HER"
About L.E.K. Consulting
We're L.E.K. Consulting, a global strategy consultancy working with business leaders to seize competitive advantage and amplify growth. Our insights are catalysts that reshape the trajectory of our clients' businesses, uncovering opportunities and empowering them to master their moments of truth. Since 1983, our worldwide practice — spanning the Americas, Europe, Middle East and Asia-Pacific — has guided leaders across all industries from global corporations to emerging entrepreneurial businesses and private equity investors. Looking for more? Visit www.lek.com.
[i] L.E.K Consulting. On the Cusp of a Cure 2025.
[ii] Huang J, Ngai CH, Deng Y, Tin MS, Lok V, Zhang L, Yuan J, Xu W, Zheng ZJ, Wong MCS. Cancer Incidence and Mortality in Asian Countries: A Trend Analysis. Cancer Control. 2022 Jan-Dec;29:10732748221095955. doi: 10.1177/10732748221095955. PMID: 35770775; PMCID: PMC9252010.
[iii] IQVIA. Rare Diseases in APAC: The Unmet Potential. Available from https://www.iqvia.com/-/media/iqvia/pdfs/asia-pacific/white-papers/rare-disease-landscape-in-the-apac-region_part-1_web-copy-4.pdf Accessed April 2025.
[iv] American Cancer Society. CAR T-cell therapy and Its Side-effects. Available from https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/car-t-cell1.html#:~:text=Chimeric%20antigen%20receptor%20(CAR)%20T,treatments%20are%20no%20longer%20working
View original content:https://www.prnewswire.com/apac/news-releases/precision-era-to-redefine-treatment-drive-450b-economic-investment-and-change-lives-across-asia-pacific-302510165.html
SOURCE L.E.K Consulting
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
China proposes global cooperation body on AI
SHANGHAI, July 27, 2025 /PRNewswire/ -- A news report from The Chinese government has proposed the establishment of a world AI cooperation organization as part of its efforts to bolster open, inclusive and equitable artificial intelligence development and governance globally. Premier Li Qiang announced the initiative when addressing the opening ceremony of the 2025 World AI Conference and High-Level Meeting on Global AI Governance in Shanghai. Li emphasized the need for collaborative approaches to global AI governance to ensure that intelligent technologies are developed for the good of all. More than 1,000 high-level representatives from upwards of 40 countries and international organizations attended the opening ceremony of the three-day event, themed "Global Solidarity in the AI Era". Li said that the risks and challenges brought by AI development, such as machine hallucinations, deep fakes and AI proliferation, have aroused widespread attention. There is an urgent need to further consolidate a societal consensus on how to achieve a balance between development and security in the AI sector, he said. Li said greater emphasis should be placed on collective governance to ensure that AI ultimately benefits humanity. Given that global AI governance appears fragmented, it is essential to enhance coordination and alignment among countries around the world to establish a framework and rules for global AI governance with a broad consensus, he added. Noting that China places great importance on global AI governance and actively participates in promoting multilateral and bilateral cooperation in this regard, the premier said the nation is willing to offer more Chinese solutions to the international community and contribute more Chinese wisdom to global AI governance. In 2023, China proposed the Global AI Governance Initiative to promote an open, inclusive and fair approach to the development and governance of AI technologies. Last year, China proposed the AI Capacity-Building Action Plan for Good and for All to bridge the AI and digital divides, and to ensure the Global South benefits equitably from AI development. China actively promotes open source development, and is willing to collaborate with countries around the world to promote progress in software and hardware technologies, intensify open source initiatives, and collectively propel AI development to higher levels, Li said. Also on July 26, the conference adopted the Global AI Governance Action Plan, which calls on all parties to work in solidarity to advance AI development and governance. For more information: View original content to download multimedia: SOURCE Sign in to access your portfolio
New York Times
7 hours ago
- New York Times
William J. Rutter, Biotech Pioneer of Gene-Based Medicine, Dies at 97
William J. Rutter, a scientist who helped create the modern biotechnology industry as a founder of a company that turned breakthroughs from academic labs into commercial medicines, including the first genetically engineered vaccine and a therapy for multiple sclerosis, died on July 11 at his home in San Francisco. He was 97. His daughter, Cindy Rutter, said the cause was complications of urothelial carcinoma, a cancer of the urinary system. In 1981, Dr. Rutter and two University of California colleagues founded the Chiron Corporation in Emeryville, Calif. Along with the South San Francisco start-up Genentech, it established the Bay Area as the country's biotech capital, a counterpart to the computing boom in Silicon Valley. Chiron specialized in recombinant DNA technology, also known as gene splicing — the technique of snipping a gene from one organism and inserting it into the DNA of another organism. In 1968 Dr. Rutter, a biochemist, was recruited by the University of California, San Francisco, to help transform it into a research powerhouse with funding from the National Institutes of Health. He helped pioneer the science of genetic engineering — a foundation of the biotech industry that set it apart from traditional pharmaceutical development. He started Chiron (pronounced KY-ron) with Pablo D. T. Valenzuela, a fellow biochemist at U.C.S.F., and Edward E. Penhoet, a professor at the University of California, Berkeley; Dr. Rutter was chairman of the board. The company was named for a centaur in Greek mythology known for his skill in the healing arts Want all of The Times? Subscribe.
Yahoo
11 hours ago
- Yahoo
Singapore skies may sparkle with two meteor showers in coming weeks
SINGAPORE – Two meteor showers, including one known for its dramatic fireballs, are set to streak across Singapore's night sky in late July and mid-August if weather conditions allow. The Delta Aquariids and the Perseids, both annual occurrences, could be visible over the next few weeks, said The Observatory at Science Centre Singapore. The Delta Aquariids, which peak around July 30, originate from Comet 96P/Machholz and appear to radiate from the constellation Aquarius. The comet was discovered in 1986 by American amateur astronomer Donald Machholz, a prolific comet hunter with more than a dozen discoveries to his name. Though not known for high meteor counts, the Delta Aquariids produce a steady stream of two to five meteors per hour, flashing into view at speeds of 40km per second. Some may leave glowing trails of gas in the sky. If cloud cover obscures the meteor shower as it peaks, stargazers may still see Saturn in the east after 11pm, according to the observatory. The Perseids – one of the best and most anticipated meteor showers of the year – will peak on the nights of Aug 12 and 13. It is best viewed during the pre-dawn hours between 3am and 6.45am, says the observatory. The Perseids are known for their high activity rate and fireballs, which leave a long glowing trail of light and colour across the sky. Under ideal conditions, up to 100 meteors may be seen in an hour. However, the 2025 Perseids may be harder to spot, as moonlight from a waning gibbous moon – a bright phase between a full and half moon – could outshine the meteors. The moon will also be near the radiant point, which is the area in the sky from where the meteors appear to emerge, making them less visible, according to the observatory. Both showers return each year as the Earth passes through dusty trails left behind by ancient comets. No special equipment is needed to view the meteor showers. The best views are expected from dark, open areas such as parks, beaches or reservoirs. The observatory will not hold special viewing events for either shower, but its regular Friday night stargazing sessions will continue. These offer telescope views of stars and planets to the public. More details are available at Source: The Straits Times © SPH Media Limited. Permission required for reproduction Discover how to enjoy other premium articles here
